Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.

Itch is the most bothersome symptom in psoriasis, often leading to impaired quality of life. Treatment of psoriasis-induced itch is frequently unsatisfactory as the various therapies employed have a delayed onset of effect. Histamine-1 receptor (H1) antihistamines are not recommended in treatment guidelines as histamine is not considered a key mediator in psoriasis. However, patients using H1 antihistamines frequently report benefits in questionnaire-based studies. To address these contradictions, we examined the short-term effects of levocetirizine, a nonsedating H1 antihistamine, on psoriasis-related itch and itch-related quality of life. In this pilot study, patients with psoriasis-relat…

The relationship between PASI and DLQI with itch, stress, and depression: Do we need additional decision‐making tools in psoriasis?

The short‐term effect of levocetirizine on quality of life, stress, and depression in itchy psoriasis patients